MorphoSys AG
21.7.2021 22:22:12 CEST | ACCESS Newswire | Press release
PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT).
MorphoSys' Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second quarter and first half financial results 2021 and provide a further outlook for 2021.
The conference call will start with a presentation by the Management Board followed by a Q&A session. Following Board Members will be on the call:
- Jean-Paul Kress, M.D., Chief Executive Officer
- Sung Lee, Chief Financial Officer
- Roland Wandeler, Ph.D., Chief Operating Officer
- Malte Peters, M.D., Chief Research & Development Officer
A live webcast and slides will be made available at the Media and Investors section under Conferences on MorphoSys' website, www.morphosys.com .
Dial-in number for the conference call (2:00pm CEST, 8:00am EDT):
Germany: +49 69 201 744 220
For UK residents: +44 203 009 2470
For US residents: +1 877 423 0830
(all numbers reachable from any geography)
Participant PIN: 72989449#
Please dial in 10 minutes before the beginning of the conference.
A replay of the conference will also be available at the corporate website following the live event.
About MorphoSys
MorphoSys (FSE:MOR)(NASDAQ:MOR) is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. In 2017, Tremfya (R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (R) (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit www.morphosys.com or www.morphosys-us.com .
Monjuvi (R) is a registered trademark of MorphoSys AG.
Tremfya (R) is a registered trademark of Janssen Biotech, Inc.
Forward Looking Statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
For more information, please contact:
Media Contacts:
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 899 27 26 079
thomas.biegi@morphosys.com
Investor Contacts:
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com
Jeanette Bressi
Director, US Communications
Tel: +1 617 404 7816
jeanette.bressi@morphosys.com
Myles Clouston
Senior Director
Tel: +1 857 772 0240
myles.clouston@morphosys.com
SOURCE: MorphoSys AG
View source version on accesswire.com:
https://www.accesswire.com/656539/Invitation-to-MorphoSys-Second-Quarter-and-First-Half-2021-Results-Conference-Call-on-July-29-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Synexis and Customate Collaborate to Advance Continuous Indoor Pathogen Control for the U.K. Poultry Industry5.10.2026 22:10:00 CEST | Press release
OVERLAND PARK, KS AND YORKSHIRE, ENGLAND / ACCESS Newswire / October 5, 2026 / Synexis®, LLC, the leader in touchless, continuous pathogen control technology, has announced a strategic collaboration with Customate Solutions, a family-owned engineering company and trusted provider of innovative manufacturing solutions with deep expertise across the poultry industry. The collaboration will bring Synexis patented DHP® technology to poultry producers throughout the United Kingdom and Ireland, helping hatcheries, poultry farms, processing facilities, and related operations strengthen indoor pathogen control while supporting modern biosecurity strategies. Poultry producers today face increasing pressure to maximize healthy hatch rates, improve chick quality, and strengthen biosecurity while reducing operational risk. Bacterial contamination on hatching eggs and throughout hatchery environments can directly impact hatchability, flock health, and production performance, making effective pathog
Chervon Names Claudio Chiappetta Vice President of Retail Sales for Chervon Canada5.10.2026 14:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 5, 2026 / Claudio Chiappetta joins Chervon as Vice President of Retail Sales for Chervon Canada; effective Monday, October 5, 2026, reporting to VP, MD Neil Harrison. A graduate of York University in Toronto, Chiappetta majored in business and marketing. He brings over 25 years of outdoor power equipment and power tool experience to Chervon as well as extensive knowledge of the Canadian home improvement and outdoor power equipment markets. Chiappetta launched his tool and outdoor career in 2003 at Black & Decker/DeWalt where he held various sales and marketing positions including cordless product manager for DeWalt Power Tools. Claudio joined TTI Milwaukee in 2008 where he was responsible for the launch of a series of Milwaukee cordless products into the Canadian market. He went on to build and manage the Ryobi outdoor power equipment portfolio along with multiple TTI power tool brands. "I am delighted to welcome Claudio to our Canadian senior
Chervon Names Daniel L. Abbott Director of Sales - Western U.S.A.5.10.2026 14:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 5, 2026 / Daniel L. Abbott joins Chervon as Director of Sales - Western U.S.A.; effective Monday, October 5, 2026, reporting to SVP Matt DeFeo. Abbott brings over 30 years of experience in the power tool, outdoor power equipment, and home improvement industry. As a graduate of Long Beach State, Abbott went on to serve for 4 years in the United States Airforce. Abbott then moved on to become a Home Depot Store Manager in Huntington Beach, California. Abbott then joined TTI/Milwaukee where he spent 24 years building, managing and leading an elite west coast-based sales team. Abbott was promoted through increasingly responsible positions until his final role as sales leader of over 700 salespeople. "Abbott is a proven and exceptional leader and mentor of high-potential sales talent," says SVP Matt DeFeo. "His obsessive focus on teaming up with key accounts at the store level has unleashed years of extraordinary growth in his areas of responsibili
Securitas Technology Releases 2027 Global Technology Outlook Report5.10.2026 14:00:00 CEST | Press release
UNIONTOWN, OH / ACCESS Newswire / October 5, 2026 / Securitas Technology, one of the world's largest electronic security companies, today announced the release of its 2027 Global Technology Outlook Report, offering organizations practical insights into the technologies, trends, and business priorities transforming the electronic security industry. Highly anticipated by security professionals across the globe - and now in its ninth annual edition - the Global Technology Outlook Report brings together perspectives from more than 16,000 end-user clients across 19 countries, independent research with more than 575 security decision-makers, 26 of the world's leading manufacturers, innovators, and Securitas Technology subject matter experts from around the world. The result is the industry's most comprehensive view of how security programs are evolving to address growing complexity, emerging risks, and rapidly changing technology. As security increasingly supports business resilience, operat
Chervon Names Peter J. Carlson Director of Sales for Strategic Accounts5.10.2026 14:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 5, 2026 / Peter J. Carlson joins Chervon as Director of Sales for Strategic Accounts effective Monday, October 5, 2026, reporting to SVP of Industrial and Commercial Sales, Jeff Campbell. Carlson brings over 27 years of power tool and outdoor product key account management experience to Chervon. A graduate of Bemidji State University in Bemidji, Minnesota; Carlson launched his career at Makita Power Tools in 1999. He progressed through a series of positions at Makita over the subsequent 10 years. In 2009, Carlson joined TTI/Milwaukee as a Senior National Account Manager. His career flourished as he was promoted through a series of increasingly responsible positions building and managing strategic key account business for TTI/Milwaukee. "Carlson is highly regarded in his ability to not only build the business but also to mentor, train and develop his people," SVP Campbell said. "His extensive experience at building store level and E-Commerce gr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom